PCIDB

KNApSAcK Metabolite C00019673

Metabolite

KNApSAcK Entry

id C00019673
Name cGMP / Cyclic GMP / 3',5'-Cyclic GMP / Guanosine 3',5'-cyclic monophosphate
CAS RN 7665-99-8
Standard InChI InChI=1S/C10H12N5O7P/c11-10-13-7-4(8(17)14-10)12-2-15(7)9-5(16)6-3(21-9)1-20-23(18,19)22-6/h2-3,5-6,9,16H,1H2,(H,18,19)(H3,11,13,14,17)/t3-,5-,6-,9-/m1/s1
Standard InChI (Main Layer) InChI=1S/C10H12N5O7P/c11-10-13-7-4(8(17)14-10)12-2-15(7)9-5(16)6-3(21-9)1-20-23(18,19)22-6/h2-3,5-6,9,16H,1H2,(H,18,19)(H3,11,13,14,17)

Cluster

Phytochemical cluster
KCF-S cluster No. 1201

Link

ChEMBL

By standard InChI CHEMBL395336
By standard InChI Main Layer CHEMBL68554 CHEMBL395336

KEGG

By LinkDB C00942

CTD

By CAS RN D006152

Species

Summary

Plant class

class name count

Family

family name count
Enterobacteriaceae 1

List (1)

* NCBI
KNApSAcK organism *ID *family *plant class *kingdom
Escherichia coli K12 83333 Enterobacteriaceae Bacteria

Human Protein / Gene in interaction

9 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
Q16281 Cyclic nucleotide-gated cation channel alpha-3 Unclassified protein CHEMBL395336 CHEMBL1629143 (1)
1 / 1
P29973 cGMP-gated cation channel alpha-1 Unclassified protein CHEMBL395336 CHEMBL1629387 (1)
1 / 1
P25098 Beta-adrenergic receptor kinase 1 Bark CHEMBL68554 CHEMBL654965 (1)
0 / 0
Q16280 Cyclic nucleotide-gated olfactory channel Unclassified protein CHEMBL395336 CHEMBL1629186 (1)
0 / 0
O15439 Multidrug resistance-associated protein 4 Unclassified protein CHEMBL395336 CHEMBL1743162 (1) CHEMBL2077477 (1)
CHEMBL2075984 (1) CHEMBL2078624 (1)
CHEMBL2077732 (1)
0 / 0
O15440 Multidrug resistance-associated protein 5 Unclassified protein CHEMBL395336 CHEMBL2075979 (1) CHEMBL2075980 (1)
0 / 0
Q96J66 ATP-binding cassette sub-family C member 11 Unclassified protein CHEMBL395336 CHEMBL2077117 (1)
1 / 0
Q13370 cGMP-inhibited 3',5'-cyclic phosphodiesterase B PDE_3B CHEMBL395336 CHEMBL764839 (1)
0 / 0
Q14432 cGMP-inhibited 3',5'-cyclic phosphodiesterase A PDE_3A CHEMBL395336 CHEMBL764839 (1)
0 / 0

CTD interaction (30)

compound gene gene name gene description interaction interaction type form reference
pmid
D006152 10257 ABCC4
EST170205
MOAT-B
MOATB
MRP4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 ABCC4 protein results in increased export of Cyclic GMP increases export
protein 16156793
D006152 10257 ABCC4
EST170205
MOAT-B
MOATB
MRP4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 ABCC4 protein results in increased transport of Cyclic GMP increases transport
protein 11856762
D006152 10257 ABCC4
EST170205
MOAT-B
MOATB
MRP4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 daidzein inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP] decreases reaction
/ increases export
protein 16156793
D006152 10257 ABCC4
EST170205
MOAT-B
MOATB
MRP4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Dipyridamole inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP] decreases reaction
/ increases transport
protein 11856762
D006152 10257 ABCC4
EST170205
MOAT-B
MOATB
MRP4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 hesperetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP] decreases reaction
/ increases export
protein 16156793
D006152 10257 ABCC4
EST170205
MOAT-B
MOATB
MRP4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 naringenin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP] decreases reaction
/ increases export
protein 16156793
D006152 10257 ABCC4
EST170205
MOAT-B
MOATB
MRP4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Probenecid inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP] decreases reaction
/ increases transport
protein 11856762
D006152 10257 ABCC4
EST170205
MOAT-B
MOATB
MRP4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Quercetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP] decreases reaction
/ increases export
protein 16156793
D006152 10257 ABCC4
EST170205
MOAT-B
MOATB
MRP4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 resveratrol inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP] decreases reaction
/ increases export
protein 16156793
D006152 10257 ABCC4
EST170205
MOAT-B
MOATB
MRP4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Silymarin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP] decreases reaction
/ increases export
protein 16156793
D006152 217 ALDH2
ALDH-E2
ALDHI
ALDM
aldehyde dehydrogenase 2 family (mitochondrial) (EC:1.2.1.3) ALDH2 protein affects the reaction [Nitroglycerin results in decreased abundance of Cyclic GMP] affects reaction
/ decreases abundance
protein 17585900
D006152 5604 MAP2K1
CFC3
MAPKK1
MEK1
MKK1
PRKMK1
mitogen-activated protein kinase kinase 1 (EC:2.7.12.2) Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein] affects reaction
/ decreases activity
/ decreases phosphorylation
protein 18225537
D006152 5604 MAP2K1
CFC3
MAPKK1
MEK1
MKK1
PRKMK1
mitogen-activated protein kinase kinase 1 (EC:2.7.12.2) Cyclic GMP results in decreased phosphorylation of MAP2K1 protein decreases phosphorylation
protein 18225537
D006152 5605 MAP2K2
CFC4
MAPKK2
MEK2
MKK2
PRKMK2
mitogen-activated protein kinase kinase 2 (EC:2.7.12.2) Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein] affects reaction
/ decreases activity
/ decreases phosphorylation
protein 18225537
D006152 5605 MAP2K2
CFC4
MAPKK2
MEK2
MKK2
PRKMK2
mitogen-activated protein kinase kinase 2 (EC:2.7.12.2) Cyclic GMP results in decreased phosphorylation of MAP2K2 protein decreases phosphorylation
protein 18225537
D006152 5599 MAPK8
JNK
JNK-46
JNK1
JNK1A2
JNK21B1/2
PRKM8
SAPK1
SAPK1c
mitogen-activated protein kinase 8 (EC:2.7.11.24) Cyclic GMP analog results in increased activity of MAPK8 protein increases activity
protein 11051267
D006152 4878 NPPA
ANF
ANP
ATFB6
CDD-ANF
PND
natriuretic peptide A Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein] affects reaction
/ decreases activity
/ decreases phosphorylation
protein 18225537
D006152 4878 NPPA
ANF
ANP
ATFB6
CDD-ANF
PND
natriuretic peptide A Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein] affects reaction
/ decreases activity
/ decreases phosphorylation
protein 18225537
D006152 10846 PDE10A
HSPDE10A
phosphodiesterase 10A (EC:3.1.4.35 3.1.4.17) Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP] decreases reaction
/ increases hydrolysis
protein 10373451
D006152 10846 PDE10A
HSPDE10A
phosphodiesterase 10A (EC:3.1.4.35 3.1.4.17) Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP] decreases reaction
/ increases hydrolysis
protein 10373451
D006152 10846 PDE10A
HSPDE10A
phosphodiesterase 10A (EC:3.1.4.35 3.1.4.17) Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP] decreases reaction
/ increases hydrolysis
protein 10373451
D006152 10846 PDE10A
HSPDE10A
phosphodiesterase 10A (EC:3.1.4.35 3.1.4.17) PDE10A protein results in increased hydrolysis of Cyclic GMP increases hydrolysis
protein 10373451
D006152 50940 PDE11A
PPNAD2
phosphodiesterase 11A (EC:3.1.4.35 3.1.4.17) 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP] decreases reaction
/ increases hydrolysis
protein 10725373
D006152 50940 PDE11A
PPNAD2
phosphodiesterase 11A (EC:3.1.4.35 3.1.4.17) Dipyridamole inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP] decreases reaction
/ increases hydrolysis
protein 10725373
D006152 50940 PDE11A
PPNAD2
phosphodiesterase 11A (EC:3.1.4.35 3.1.4.17) PDE11A protein results in increased hydrolysis of Cyclic GMP increases hydrolysis
protein 10725373
D006152 50940 PDE11A
PPNAD2
phosphodiesterase 11A (EC:3.1.4.35 3.1.4.17) zaprinast inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP] decreases reaction
/ increases hydrolysis
protein 10725373
D006152 8654 PDE5A
CGB-PDE
CN5A
PDE5
phosphodiesterase 5A, cGMP-specific (EC:3.1.4.35) PDE5A protein results in decreased abundance of Cyclic GMP decreases abundance
protein 10422958
D006152 5152 PDE9A
HSPDE9A2
phosphodiesterase 9A (EC:3.1.4.35) PDE9A protein results in increased hydrolysis of Cyclic GMP increases hydrolysis
protein 9624146
D006152 5152 PDE9A
HSPDE9A2
phosphodiesterase 9A (EC:3.1.4.35) zaprinast inhibits the reaction [PDE9A protein results in increased hydrolysis of Cyclic GMP] decreases reaction
/ increases hydrolysis
protein 9624146
D006152 6794 STK11
LKB1
PJS
hLKB1
serine/threonine kinase 11 (EC:2.7.11.1) STK11 protein promotes the reaction [Histamine results in increased abundance of Cyclic GMP] increases abundance
/ increases reaction
protein 21145922

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (3)

OMIM preferred title UniProt
#216900 Achromatopsia 2; achm2 Q16281
#117800 Apocrine gland secretion, variation in Q96J66
#613756 Retinitis pigmentosa 49; rp49 P29973

KEGG DISEASE (2)

KEGG disease name UniProt
H00527 Retinitis pigmentosa (RP) P29973 (related)
H00971 Achromatopsia Q16281 (related)

Diseases related to CTD interactions

7 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D004409 D006152 Dyskinesia, Drug-Induced therapeutic
189712
D006333 D006152 Heart Failure marker/mechanism
1647690
D006930 D006152 Hyperalgesia marker/mechanism
16098672
D006973 D006152 Hypertension marker/mechanism
17210833
D008881 D006152 Migraine Disorders marker/mechanism
10376166
D020326 D006152 Migraine without Aura marker/mechanism
11304026
D013375 D006152 Substance Withdrawal Syndrome therapeutic
10422958